ArticleExperimental hematology & oncology2025

Safety and efficacy of CD33-targeted CAR-NK cell therapy for relapsed/refractory AML: preclinical evaluation and phase I trial.

Ruihao Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.